G2GBio has been selected for a government-supported project by the Ministry of SMEs and Startups, receiving 11.4 billion won in funding over three years.

-  Research and development project for a one-month sustained-release schizophrenia treatment

-  The goal is to replace once-daily oral administration with a formulation that enhances therapeutic effects.

Based on G2GBio's patented platform technology, research on a sustained-release schizophrenia treatment has been selected as a new supported project under the Small and Medium Venture Business Department's 2024 Small Business Technology Innovation Development Project (Market Expansion Type, Scale-up TIPS).

G2GBio announced on the 30th that it will receive exclusive government funding of 11.4 billion won for the next three years.

The Small and Medium Venture Business Department's Scale-up TIPS (Technology Innovation Development Project for SMEs) is a national project aimed at fostering challenges, innovations, and scale-ups of manufacturing, hardware-based, and technology-intensive SMEs by connecting private investment with government funds.

The research selected for this national project aims to develop a schizophrenia treatment that lasts for one month using G2G Bio's drug delivery technology, InnoLAMP.

While there is a growing trend in long-acting injectable drugs that offer convenience and increased therapeutic effects, commercialized injectables require improvements such as reducing discomfort associated with high dosages.

G2GBio aims to develop high-dose products to significantly reduce dosage and address unmet patient needs, thereby improving medication adherence.

Seol Eun-young, the research director for this project at G2G Bio, stated, "We have already confirmed in preliminary testing that it is possible to control the pharmacokinetic profile with high-dose formulations." She added, "Now that we have been selected for the national project, our plan is to secure the final candidate formulation and proceed with comprehensive animal efficacy testing, toxicity testing, and scale-up research."